CYCN
Income statement / Annual
Last year (2024), Cyclerion Therapeutics, Inc.'s total revenue was $2.00 M,
and the percentage change from the previous year is not available.
In 2024, Cyclerion Therapeutics, Inc.'s net income was -$3.06 M.
See Cyclerion Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$2.00 M |
$0.00 |
$297.00 K |
$3.32 M |
$2.30 M |
$4.51 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$5.58 M
|
$0.00
|
$56.41 M
|
$95.14 M
|
$1.53 M
|
$1.75 M
|
$2.17 M
|
| Gross Profit |
$2.00 M
|
$0.00
|
-$5.28 M
|
$3.32 M
|
-$54.12 M
|
-$90.63 M
|
-$1.53 M
|
-$1.75 M
|
-$2.17 M
|
| Gross Profit Ratio |
1
|
0
|
-17.78
|
1
|
-23.57
|
-20.11
|
0
|
0
|
0
|
| Research and Development Expenses |
$286.00 K
|
$1.52 M
|
$5.98 M
|
$37.64 M
|
$56.41 M
|
$95.14 M
|
$87.72 M
|
$78.80 M
|
$50.90 M
|
| General & Administrative Expenses |
$5.34 M
|
$8.13 M
|
$12.86 M
|
$20.62 M
|
$28.82 M
|
$34.40 M
|
$27.54 M
|
$15.12 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$200.00 K
|
$400.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.34 M
|
$8.33 M
|
$13.26 M
|
$20.62 M
|
$28.82 M
|
$34.40 M
|
$27.54 M
|
$15.12 M
|
$10.48 M
|
| Other Expenses |
$0.00
|
$3.10 M
|
-$5.98 M
|
$259.00 K
|
-$58.08 M
|
-$95.14 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$5.63 M
|
$12.95 M
|
$13.26 M
|
$58.52 M
|
$27.15 M
|
$34.40 M
|
$115.25 M
|
$93.92 M
|
$61.38 M
|
| Cost And Expenses |
$5.63 M
|
$12.95 M
|
$18.84 M
|
$58.52 M
|
$83.56 M
|
$129.54 M
|
$115.25 M
|
$93.92 M
|
$63.55 M
|
| Interest Income |
$208.00 K
|
$358.00 K
|
$294.00 K
|
$0.00
|
$588.00 K
|
$2.03 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$16.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$65.00 K
|
$65.00 K
|
$472.00 K
|
$2.30 M
|
$2.70 M
|
$1.53 M
|
$1.75 M
|
$2.17 M
|
| EBITDA |
-$3.63 M |
-$9.58 M |
-$18.48 M |
-$53.84 M |
-$80.64 M |
-$122.34 M |
-$113.72 M |
-$92.18 M |
-$61.38 M |
| EBITDA Ratio |
-1.81
|
0
|
-62.21
|
-16.22
|
-35.12
|
-27.14
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.81
|
0
|
-62.42
|
-16.63
|
-35.39
|
-27.74
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$571.00 K
|
$358.00 K
|
$294.00 K
|
$3.55 M
|
$3.46 M
|
$2.03 M
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$3.06 M
|
-$12.59 M
|
-$18.25 M
|
-$51.65 M
|
-$77.80 M
|
-$123.01 M
|
-$115.25 M
|
-$93.92 M
|
-$63.55 M
|
| Income Before Tax Ratio |
-1.53
|
0
|
-61.43
|
-15.56
|
-33.89
|
-27.29
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$3.06 M
|
-$5.26 M
|
-$44.08 M
|
-$51.65 M
|
-$77.80 M
|
-$123.01 M
|
-$115.25 M
|
-$93.92 M
|
-$63.55 M
|
| Net Income Ratio |
-1.53
|
0
|
-148.41
|
-15.56
|
-33.89
|
-27.29
|
0
|
0
|
0
|
| EPS |
-1.21 |
-8.99 |
-20.15 |
-26.4 |
-47.8 |
-88.37 |
-84.42 |
-68.8 |
-46.39 |
| EPS Diluted |
-1.21 |
-8.99 |
-20.15 |
-26.4 |
-47.8 |
-88.37 |
-84.42 |
-68.8 |
-46.39 |
| Weighted Average Shares Out |
$2.52 M
|
$2.34 M
|
$2.17 M
|
$1.96 M
|
$1.52 M
|
$1.37 M
|
$1.37 M
|
$1.37 M
|
$1.37 M
|
| Weighted Average Shares Out Diluted |
$2.52 M
|
$2.34 M
|
$2.17 M
|
$1.96 M
|
$1.52 M
|
$1.37 M
|
$1.37 M
|
$1.37 M
|
$1.37 M
|
| Link |
|
|
|
|
|
|
|
|
|
